Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer
Conditions
Brief summary
The combination of paclitaxel and carboplatin is the standard first-line chemotherapy for ovarian cancer as recommended by the NCCN Guidelines for Epithelial Ovarian Cancer, and is conventionally given via intravenous route every three weeks. The addition of target therapy (bevacizumab) has shown to improve progression free survival but not overall survival. Several trials have also demonstrated a clinically significant survival advantage associated with intraperitoneal chemotherapy compared to intravenous chemotherapy, and the best outcomes are consistently seen for patients who have no residual disease. This study aims to compare triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.
Interventions
DRUGChemotherapy
Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
Sponsors
Far Eastern Memorial Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* women aged 20 and above with FIGO stage II-IV advanced ovarian, fallopian tube or primary peritoneal cancer who received debulking surgery, followed by either triweekly intravenous chemotherapy with bevacizumab or intraperitoneal chemotherapy; women who received neoadjuvant chemotherapy followed by interval debulking surgery were also eligible for participation. Intraperitoneal chemotherapy was defined as having one or more cycles of an intraperitoneal regimen administered.
Exclusion criteria
* women who quit half-way or received chemotherapy at other site
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | the time interval from the date of surgery or neoadjuvant chemotherapy to clinically defined recurrence, disease progression, or the last follow-up |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | the time interval from the date of surgery or neoadjuvant chemotherapy to the date of death from any cause or the last follow-up |
Countries
Taiwan
Outcome results
None listed